These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38604197)

  • 1. Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake - Authors' reply.
    Israelsen M; Rinella ME; Krag A
    Lancet Gastroenterol Hepatol; 2024 May; 9(5):409-410. PubMed ID: 38604197
    [No Abstract]   [Full Text] [Related]  

  • 2. Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake.
    Wu Y; Fang F
    Lancet Gastroenterol Hepatol; 2024 May; 9(5):409. PubMed ID: 38604196
    [No Abstract]   [Full Text] [Related]  

  • 3. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
    Kim GA; Moon JH; Kim W
    Clin Mol Hepatol; 2023 Oct; 29(4):831-843. PubMed ID: 37634892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
    Canivet CM; Boursier J; Loomba R
    Semin Liver Dis; 2024 Feb; 44(1):35-42. PubMed ID: 38531378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alcohol Intake Thresholds Among Individuals With Steatotic Liver Disease.
    Yeo YH; Zhu Y; Arab JP; Ni W; Xu X; Shi J; Li J
    JAMA Netw Open; 2023 Dec; 6(12):e2347548. PubMed ID: 38095900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steatotic liver disease phenotypes in the United States: The impact of alcohol consumption assessment.
    Ciardullo S; Perseghin G
    J Hepatol; 2024 May; 80(5):e203-e204. PubMed ID: 37813242
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of past and present alcohol use in steatotic liver disease.
    Åberg F
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):188-189. PubMed ID: 38218201
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: Mendelian randomisation to investigate moderate alcohol consumption in nonalcoholic fatty liver disease; modest effects need large numbers-authors' reply.
    Sookoian S; Pirola CJ
    Aliment Pharmacol Ther; 2017 Aug; 46(4):469-470. PubMed ID: 28707786
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity-authors' reply.
    Barone M; Viggiani MT; Losurdo G; Principi M; Leandro G; Di Leo A
    Aliment Pharmacol Ther; 2017 Aug; 46(4):460-461. PubMed ID: 28707799
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter: Are we forgetting the importance of steatosis in steatotic liver disease? Authors' reply.
    Kuo SZ; Loomba R
    Aliment Pharmacol Ther; 2024 Jan; 59(2):297-298. PubMed ID: 38153275
    [No Abstract]   [Full Text] [Related]  

  • 12. [Metabolic steatotic liver disease: the move towards an inclusive definition].
    Zampaglione L; Marello N; Petignat PA
    Rev Med Suisse; 2024 Feb; 20(860):311-315. PubMed ID: 38323767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease, alcohol intake and psoriasis.
    Bordignon M; Viel G; Peserico A; Alaibac M
    J Hepatol; 2010 Sep; 53(3):587. PubMed ID: 20561701
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial: Crystalising the burden of steatotic liver disease-Authors' reply.
    Schneider CV; Schneider KM; Loomba R
    Aliment Pharmacol Ther; 2024 May; 59(10):1294-1295. PubMed ID: 38652769
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: Detecting unreported alcohol consumption in patients with NAFLD - Standardisation is urgent. Authors' reply.
    Lefere S; Geerts A
    Aliment Pharmacol Ther; 2023 Nov; 58(9):969-970. PubMed ID: 37831534
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: The tsunami of steatotic liver disease in India, the Asia-Pacific region and the world-Authors' reply.
    Prasad M; Prabhakar T; Sarin SK
    Aliment Pharmacol Ther; 2024 Apr; 59(7):902-903. PubMed ID: 38462700
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial: trends in alcohol use and alcohol-associated liver disease in the US population-authors' reply.
    Singal AK; Arsalan A; Dunn W; Arab JP; Wong RJ; Kuo YF; Kamath PS; Shah VH
    Aliment Pharmacol Ther; 2021 Aug; 54(4):513-514. PubMed ID: 34331802
    [No Abstract]   [Full Text] [Related]  

  • 18. Biphasic effect of alcohol intake on the development of fatty liver disease.
    Takahashi H; Ono M; Hyogo H; Tsuji C; Kitajima Y; Ono N; Eguchi T; Fujimoto K; Chayama K; Saibara T; Anzai K; Eguchi Y
    J Gastroenterol; 2015 Nov; 50(11):1114-23. PubMed ID: 25733100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.
    Iwasa M; Sugimoto R; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):793-801. PubMed ID: 38526942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calorie and alcohol consumption in nonalcoholic fatty liver disease.
    Marks P; Williams R
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):527-30. PubMed ID: 22343784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.